Topical corticosteroids (TCS)

DRUG3 trials

Conditions

Atopic Dermatitis

Phase 3

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Active, not recruitingNCT03568318

AbbVieAtopic Dermatitis

Start: 2018-08-09End: 2030-10-23Updated: 2025-12-23

A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

CompletedNCT03661138

AbbVieAtopic Dermatitis

Start: 2018-10-27End: 2022-08-19Updated: 2023-03-01

Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis

CompletedNCT04587453

LEO PharmaAtopic Dermatitis

Start: 2020-10-27End: 2021-07-15Updated: 2025-03-11

SKIN The Journal of Cutaneous Medicine2026-03-10

Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)

SKIN The Journal of Cutaneous Medicine2025-11-101 citations

Patients With Atopic Dermatitis Using Oral Contraceptive Pills or Hormone Replacement Therapy: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)

SKIN The Journal of Cutaneous Medicine2025-11-101 citations

Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks.

2025-09-031 citations

Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease.

2025-08-282 citations

Impact of Achieving Optimal Treatment Targets and Minimal Disease Activity on Health-Related Quality of Life and Satisfaction in Patients with Atopic Dermatitis.

2025-06-26

Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis

JAMA Dermatology2024-10-238 citations

649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials

British Journal of Dermatology2024-08-013 citations

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study.

2024-05-025 citations

Safety of Tralokinumab for the Treatment of Atopic Dermatitis in Patients with Up to 4.5 Years of Treatment: An Updated Integrated Analysis of Eight Clinical Trials

SKIN The Journal of Cutaneous Medicine2024-03-183 citations

555 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials

British Journal of Dermatology2024-02-011 citations

Atopische Dermatitis: Zuverlässigkeit von PROs und deren Bedeutung in klinischer Praxis

Kompass Dermatologie2024-01-01

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Dermatology and Therapy2023-12-2110 citations

Psychometric evaluation of the Worst Pruritus Numerical Rating Scale (NRS), Atopic Dermatitis Symptom Scale (ADerm-SS), and Atopic Dermatitis Impact Scale (ADerm-IS)

Current Medical Research and Opinion2023-09-113 citations

Acne Among Japanese Patients with Atopic Dermatitis Receiving Upadacitinib in the Phase 3 Rising Up Study

Dermatology and Therapy2023-06-258 citations

403 Achievement of minimal disease activity is associated with improvements in symptoms, quality of life and treatment satisfaction in patients with atopic dermatitis

British Journal of Dermatology2023-06-014 citations

413 Improvement in itch, symptoms and quality of life with upadacitinib through week 16 in adults and adolescents with atopic dermatitis: results from phase 3 studies (Measure Up 1, Measure Up 2 and AD Up)

British Journal of Dermatology2023-06-011 citations

Upadacitinib for moderate‐to‐severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics

Journal of the European Academy of Dermatology and Venereology2023-05-2919 citations

Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis

JAMA Dermatology2023-04-1256 citations

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

RMD Open2023-02-01180 citations

7 more papers not shown

Topical corticosteroids (TCS)

Sponsors

Conditions

Phase 3

Related Papers